A retrospective evaluation of 200 consecutive recipients of autologous peripheral blood stem cell transplantation was conducted to ascertain the incidence and outcome of Streptococcus viridans bacteremia as well as to determine the role of prophylactic ampicillin therapy in the peri-transplant setting. Viridans streptococci were isolated from the blood of 35 individuals at a median of 6 days (range 2-8 days) following stem cell infusion. The most common isolates were S. sanguis and S. mitis. All patients received ciprofloxacin orally during the peritransplant period. Additionally, 79 patients received oral ampicillin prophylactically against gram-positive cocci. Although none of the patients suffered a fatal outcome, three individuals developed respiratory compromise requiring mechanical ventilation. Female sex proved to be the only independent risk factor for viridans streptococcal bacteremia (P = 0.04). The shorter duration of neutropenia observed after stem cell transplantation did not impact on the incidence of S. viridans infections. Moreover, the prophylactic use of ampicillin failed to decrease the incidence of viridans sepsis and selected out organisms that were resistant to betalactam antibiotics. Keywords: Streptococcus viridans; autologous stem cell transplantation Gram-positive cocci are the most commonly isolated bacteria following allogeneic and autologous bone marrow transplantation (BMT). Streptococcus viridans is identified frequently and can result in significant morbidity and occasional mortality. A recent trend has been the increased utilization of autologous peripheral blood stem cell transplantation (PBSCT) in combination with growth factors. This has resulted in a significant reduction in the duration of neutropenia with the potential for fewer early bacterial infections. We evaluated the incidence and outcome of S. viridans bacteremia in 200 consecutive recipients of autologous PBSCT for a variety of solid tumors (ST) and hematologic malignancies (HM).
Materials and methods
Two hundred consecutive patients underwent autologous PBSCT between March 1993, and August 1996, at the University of Connecticut Health Center, Farmington, CT, and were eligible for retrospective evaluation. Clinical data were obtained from comprehensive chart reviews of all patients (Table 1 ). Blood cultures were only performed during a febrile episode and subsequently as indicated clinically. S. viridans bacteremia was defined as at least one positive blood culture during the period of neutropenia following autologous PBSCT. Organ dysfunction was attributed to S. viridans if it occurred within 1 week of the last positive blood culture and could not be explained by any other underlying factor.
1 S. viridans toxic shock syndrome was defined as respiratory failure and/or hypotension related to S. viridans bacteremia. 2 The underlying malignancies included carcinoma of the breast (n = 99), non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) (n = 65), multiple myeloma (n = 14), acute leukemia (n = 6), ovarian carcinoma (n = 7), and other ST (n = 9). Conditioning chemotherapy regimens were busulfan 16 mg/kg, cyclophosphamide 90 mg/kg, and etoposide 60 mg/kg (BUCET) (n = 69), busulfan 16 mg/kg, thiotepa 500-700 mg/m 2 , and carboplatin 800-1000 mg/m 2 (BUCAT) (n = 126), and other regimens (n = 5). A Hickman-type double or triple lumen central venous cathether (CVC) was inserted prior to transplantation. All patients were evaluated by specialists in oral diagnosis, and any corrective dental surgery was performed at least 2 to 3 months prior to PBSCT. During the transplant admission, the oral cavity-care protocol consisted of nystatin liquid one million units swish and swallow four times daily, chlorhexidine mouthwash 15 ml swish and expectorate twice daily, and half-strength hydrogen peroxide swish and expectorate four times daily. All 200 patients received ciprofloxacin 500 mg orally twice daily from the beginning of conditioning chemotherapy (day −8 to day −10) till engraftment /l) or initiation of parenteral antibiotics. The last 79 patients also received ampicillin 250 mg orally four times daily from day +2 until engraftment or initiation of parenteral antibiotics. During aplasia, all febrile episodes were treated initially with ceftazidime 1 g intravenously three times daily or a related broad-spectrum antibiotic. Oral trimethoprimsulphamethoxazole was not utilized for prophylaxis against Pneumocystis carinii until complete recovery of the peripheral blood counts. Acyclovir 250 mg/m 2 intravenously three times daily was administered prophylactically from the initiation of conditioning chemotherapy until engraftment and was then continued orally at a dose of 400 mg twice daily till day +50 in all individuals who were sero-positive for the herpes simplex virus. Moreover, compliance with prophylactic oral antibiotic therapy was not an issue because all patients remained hospitalized from day −8 or −10 until engraftment.
Several variables were examined as potential risk factors for S. viridans infection. These included age, sex, duration of neutropenia, underlying malignancy, and conditioning chemotherapy regimen. Contingency table ( 2 ) analyses were used to estimate the statistical significance of each discrete variable. Continuous variables were compared using the median test. Finally, the joint effect of combinations of variables as a set of risk factors for infection was assessed using a logistic regression model.
Results

Incidence
A total of 35 patients (17.5%) developed S. viridans bacteremia. No individual had more than a single positive blood culture. S. viridans was also identified in the cerebrospinal fluid of one patient where it was presumed to be a contaminant from the blood. The median duration of neutropenia in all 200 patients was 7 days (range 3-12 days); it was also 7 days (range 3-12 days) in those who did not develop S. viridans infection and 7 days (range 4-12 days) in those individuals in whom S. viridans was isolated. The median day following stem cell infusion (day 0) at which engraftment took place was day +9 (range day +7 to day +13). The median day at which S. viridans was isolated from the blood was day +6 (range day +2 to day +8). S. viridans bacteremia never occurred after engraftment. The incidence of S. viridans infection in patients who received (n = 79) or did not receive (n = 121) prophylactic oral ampicillin was 15.2 and 19%, respectively, a difference that was not statistically significant (P = 0.63). Of note, the groups of patients either treated or not treated prophylactically with ampicillin were matched for age, sex, duration of neutropenia and underlying malignancy. However, BUCAT was administered to 78% of patients receiving ampicillin, and to 49% of individuals not receiving ampicillin.
Species and sensitivity
All except one of the S. viridans isolates were sub-speciated and included S. sanguis (n = 18), S. mitis (n = 15), and S. salivarius (n = 1). Nine isolates demonstrated in vitro resistance to beta-lactam antibiotics such as penicillin G and cephalosporins. Seven of these isolates were identified from a group of 12 patients who developed S. viridans infection while receiving oral ampicillin whereas only two of 23 individuals not receiving ampicillin developed an infection with penicillin-resistant strains. All penicillinresistant species were sensitive to vancomycin (Table 2) .
Clinical features and outcome
Fever was the presenting symptom in all 35 patients. Three females with carcinoma of the breast developed the S. viridans toxic shock syndrome within 48 h of bacteremia and required mechanical ventilation. One of these patients became obtunded. Magnetic resonance imaging of the brain was unremarkable and electroencephalography revealed diffuse slow waves. S. viridans was isolated from the cerebrospinal fluid on one occasion and was considered a contaminant from the blood. She remains in persistent vegetative state more than 9 months following PBSCT. All three instances of S. viridans toxic shock syndrome were associated with S. mitis. None of the patients died as a result of S. viridans infection. All three individuals received methylprednisone 1-2 mg/kg body weight intravenously every 6 h until they were extubated.
Risk factors
All 200 individuals were included in the statistical analysis because there was no early mortality prior to engraftment. All patients developed severe oral mucositis requiring intravenous narcotics for control of pain. Moreover, the incidence of early oral herpes simplex virus infection or reactivation was negligible and did not contribute to the mucositis. Female sex was the only variable which achieved statistical significance (P = 0.04) in predicting an increasing propensity towards acquiring S. viridans. All other potential risk factors failed to predict an increased risk for S. viridans infection (Table 3) . We also investigated the utility of a logistic regression model to ascertain the joint risk of infection based on sex, age, underlying malignancy, type of conditioning regimen and duration of neutropenia. Only sex entered the model with male sex being protective. The estimated relative risk for acquiring viridans Table 2 Impact of prophylactic ampicillin on viridans streptococcal infection Table 3 Incidence of viridans streptococci in various patient subgroups streptococcal infection was 0.328 for males compared with females (95% confidence interval = 0.110, 0.981).
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Other infections
As many as 164 patients developed a fever greater than 38°C while neutropenic. Sixty-three organisms were isolated from the blood of 59 individuals. Apart from viridans streptococci, other organisms included Staphylococcus epidermidis (n = 12), other Staphylocci (n = 4), Enterococci (n = 6), gram-negative rods (n = 3), Corynebacterium species (n = 1) and Candida species (n = 2).
Discussion
Oral fluoroquinolones are capable of eliminating Enterobacteriaceae from the gastrointestinal tract without affecting anaerobic and most gram-positive flora. 3, 4 In fact, viridans streptococci which are normal commensals of the oral cavity and gastrointestinal tract, are usually resistant to fluoroquinolones and may actually proliferate and translocate in their presence. 5 The incidence of early gram-negative bacteremia has decreased with the prophylactic use of fluoroquinolones in the peri-transplantation setting. 6, 7 At the same time, however, infection with gram-positive cocci, most notably S. viridans, has increased considerably. The incidence of S. viridans bacteremia following allogeneic BMT has ranged from 0 to 46.2%. [8] [9] [10] [11] Furthermore, in several other series of patients undergoing both allogeneic and autologous BMT, the incidence has varied from 9 to 28.6%. 5, [12] [13] [14] [15] The most frequently isolated subtypes of S. viridans have been S. sanguis and S. mitis, accounting for 75% of isolates in one large series. 1 Both of these subtypes of S. viridans streptococci are capable of elaborating immunoglobulin A1 proteases which could potentially impair local defenses. 16 A recent meta-analysis indicated that a combination of fluoroquinolones and prophylaxis against gram-positive organisms reduces the occurrence of gram-positive bacteremia in granulocytopenic patients. 17 The addition of erythromycin to ciprofloxacin prophylaxis failed to be of any benefit following transplantation in one study. 18 However, the use of alternative agents with activity against gram-positive organisms such as oral roxithromycin, 19, 20 intravenous penicillin, 21 intravenous cephalothin, 19 oral amoxicillin, 22 oral rifampicin 23 and intravenous vancomycin 24 have all significantly reduced the incidence of viridans streptococcal bacteremia. Viridans streptococcal bacteremia was observed in 17.5% of our patients undergoing autologous PBSCT. Even though the incidence was not affected by the prophylactic use of ampicillin, the isolation of strains that were resistant to beta-lactam antibiotics increased dramatically. As many as 26% of S. viridans isolates obtained from individuals on no prior antimicrobial prophylaxis can be resistant to ampicillin. 15 The mechanism underlying this resistance has been attributed to the diminished affinity of penicillin-binding proteins for penicillin. 25 Moreover, the use of intravenous vancomycin as prophylactic therapy has the potential for the emergence of vancomycin-resistant organisms. On the other hand, more than 90% of S. viridans isolates can be susceptible to the newer macrolides, rifampicin and minocycline. 26 Risk factors for the development of viridans streptococcal bacteremia in all granulocytopenic patients include severe neutropenia, prophylaxis with co-trimoxazole or fluoroquinolones, high doses of cytosine arabinoside, oral mucositis, and the use of H2-receptor blocking agents. 27 After bone marrow transplantation, risk factors for viridans streptococcal infection were previously identified and include the presence of herpes simplex virus in the oral cavity 9 although this has been disputed, 28 higher dose of radiation therapy to the oral cavity resulting in increased mucositis, 28 the use of anthracyclines or cytosine arabinoside in the transplant conditioning regimen, 11 children, 12 or adults, 15 an underlying diagnosis of lymphoma 15 or Ewing's sarcoma, 29 and the purging of autologous bone marrow with monoclonal antibodies and rabbit complement. 12, 30 In one large series, univariate analysis demonstrated a significance for age less than 18 years, autologous BMT, acute lymphoblastic leukemia and cytosine arabinoside-containing regimens whereas multivariate analysis identified only age less than 18 years and acute lymphoblastic leukemia as significant risk factors for S. viridans bacteremia. Female sex proved to be the only significant risk factor in our study. Other investigators have also found an increased incidence of S. viridans infection in females, 31 but the reason for this predisposition is unclear. More notably, the type of underlying malignancy and conditioning chemotherapy regimen, prophylactic use of ampicillin, age, and duration of neutropenia failed to achieve statistical significance in both univariate and multivariate analyses.
Although the course is usually benign, as many as onethird of granulocytopenic patients with S. viridans infection can develop hypotension, shock, neurologic impairment, and adult respiratory distress syndrome requiring inotropic support and mechanical ventilation. 27 Following bone marrow transplantation, the incidence of this major complication, also known as alpha-streptococcal toxic shock syndrome, ranges from 8 to 33% and can result in a fatal outcome in 60 to 100% of instances.
1,2,13,14,29 S. mitis is the most frequently isolated subtype. 2, 27 The only previously identified risk factor is age less than 15-16 years.
2,14 The development of pneumonitis or neurologic complications are considered poor prognostic signs. 29 The pathophysiology is unclear but may be related to capillary endothelial damage and permeability resulting from the release of cytokines such as tumor necrosis factor alpha, interleukin-1 and interleukin-6. 27 The syndrome tends to occur 24-48 h after S. viridans bacteremia is first detected, 14 and the initiation of parenteral antibiotics including vancomycin does not appear to have an impact on survival. 2 Autopsy findings include hyaline membrane formation and diffuse alveolar damage in the lungs, myocardial edema, and cerebral cortical degeneration.
2,14 Three of our patients developed respiratory failure requiring mechanical ventilation. Notably, S. mitis which was resistant to beta-lactam antibiotics was isolated from all three patients. Although there was no mortality, one individual was left with permanent neurologic deficits. The use of high doses of parenteral corticosteroids may have altered the clinical course of this syndrome in our patients, and resulted in a relatively favorable outcome compared to previous reports.
This study represents the first large report of viridans streprococcal infection following autologous PBSCT. The shorter duration of neutropenia in such transplants does not appear to affect the incidence of these infections. A small subset of patients can develop respiratory and hemodynamic compromise, resulting in significant morbidity. The prophylactic use of ampicillin does not appear to impact upon the incidence of S. viridans bacteremia and tends to select out organisms that are resistant to beta-lactam antibiotics. The utility of other antibiotics with activity against streptococci such as the newer macrolides 32 or rifampicin 33 deserves to be studied further in the peri-transplant setting.
